Early precursor T-cell acute lymphoblastic leukemia
Conditions
Interventions
Case series:Venetoclax+HAG solution
Sponsors
The First Affiliated Hospital, Zhejiang University College of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged > 18 years; 2. The cell morphology and immunophenotype at the initial diagnosis are consistent with the diagnosis of ETP-ALL; 3. Refractory ETP-ALL (initially diagnosed ETP-ALL, failed to achieve remission after 2 standard treatment regimens) or relapsed ETP-ALL (after remission, the bone marrow blast cells were again greater than 20%, and the leukemia cell morphology and immunophenotype were consistent with ETP- ALL); 4. The ECOG score during screening is 0-2 points; 5. Expected survival period >= 2 months; 6. During the screening period, there is no abnormal organ function that restricts the use of the program; 7. Understand the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Refractory/relapsed ETP-ALL patients who cannot be treated with Venetoclax due to economic constraints; 2. History of other malignant tumors in the past 5 years; 3. Serum total bilirubin > 1.5 ULN (upper limit of normal); ALT or AST or ALP > 5 ULN; serum creatinine > 1.5 ULN; 4. Known HIV infection, or chronic infection with hepatitis B virus (HbsAg positive) or hepatitis C virus (anti-HCV positive); 5. The general condition is not suitable for chemotherapy; 6. Failure to comply with the research protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate;Partial remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mutational analysis;Gene fusion analysis;Karyotype analysis; | — |
Countries
China
Contacts
Public ContactJin Jie
The First Affiliated Hospital, Zhejiang University College of Medicine
Outcome results
None listed